Running summarizing tools on a new article
Check the paper below, then start its synthesis.
Model-based integration of chimeric antigen receptor T-cell kinetics and tumor features to predict therapeutic outcomes in patients with B-cell malignancies
Jonas Schadt (University Hospital Carl Gustav Carus, Technische Universität Dresden), Maximilian Alexander Röhnert (University Hospital Carl Gustav Carus, Technische Universität Dresden), Paul Matthiensen (University Hospital Carl Gustav Carus, Technische Universität Dresden), Uta Oelschlägel (University Hospital Carl Gustav Carus, Technische Universität Dresden), Martin Bornhäuser (University Hospital Carl Gustav Carus, Technische Universität Dresden), Frank Kroschinsky (University Hospital Carl Gustav Carus, Technische Universität Dresden), Raphael Teipel (University Hospital Carl Gustav Carus, Technische Universität Dresden), Ingmar Glauche (Technische Universität Dresden), Malte v. Bonin (University Hospital Carl Gustav Carus, Technische Universität Dresden), Artur C. Fassoni (Technische Universität Dresden, Universidade Federal de Itajubá)
Abstract: Introduction: Chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for several hematological malignancies, yet patient-specific responses and toxicities remain hard to predict. Although multiple covariates and risk scores exist, their prognostic accuracy remains limited. Methods: We prospectively measured CAR T-cell kinetics in peripheral blood of 92 patients with B-cell malignancies using multicolor flow cytometry. To explore underlying mechanisms, we developed a mechanistic model of CAR T-cell and tumor cell interactions. Results: We captured four phases of CAR T-cell kinetics in peripheral blood: distribution, expansion, contraction, and persistence. Patients with weak expansion or deep contraction are more likely to relapse. When fitted to the 46 patients with suDicient data points, the model reproduces individual CAR T-cell kinetics but fails to predict outcomes using uniform tumor parameters. We demonstrate that identical CAR T-cell dynamics may result from diDerent tumor features, including growth rate, initial burden, or antigen density. Accurately estimating these tumor-specific factors may improve relapse prediction, while common surrogates like blood lactate dehydrogenase, International Prognostic Index score, or Ann-Arbor stage do not. Conclusion: We conclude that CAR T-cell kinetics within the first month can serve as early prognostic markers. Integrating tumor burden estimates is required to reconcile kinetics with individual outcomes and may, upon prospective validation, further improve risk stratification in patients with B-cell malignancies receiving CAR T-cell therapy.